European Society of Hypertension Working Group on Obesity: Background, aims and perspectives

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 897-900

  Jordan, Jens ^a,f   Engeli, Stefan ^a   Redon, Josep ^b   Sharma, Arya M ^c   Luft, Friedrich C ^a   Narkiewicz, Krzysztof ^d   Grassi, Guido ^e  

^a FRANZ VOLHARD CLINIC   (Germany)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c MCMASTER UNIVERSITY   (Canada)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e SAN GERARDO HOSPITAL   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; ENVIRONMENTAL FACTOR; EXERCISE; GENETIC ASSOCIATION; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICAL PRACTICE; MEDICAL SOCIETY; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SODIUM RETENTION; SYMPATHETIC TONE; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; EUROPE; HUMANS; HYPERTENSION; OBESITY; SOCIETIES, MEDICAL; SYMPATHETIC NERVOUS SYSTEM; WEIGHT LOSS;

EID: 33947098484     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328051b510     Document Type: Review

References (36)

1. WHO. Obesity - preventing and managing the global epidemic. WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva: WHO; 1997.
2. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649.
3. Han TS, Van Leer EM, Seidell JC, Lean ME. Waist circumference as a screening tool for cardiovascular risk factors: evaluation of receiver operating characteristics (ROC). Obes Res 1996; 4:533-547.
4. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-1529.
5. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-1872.
6. Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes 2002; 26:48-57.
7. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36:531-537.
8. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106:2533-2536.
9. Stelfox HT, Ahmed SB, Ribeiro RA, Gettings EM, Pomerantsev E, Schmidt U. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006; 34:1243-1246.
10. Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, et al. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 2006; 24:1633-1639.
11. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
12. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14:694-698.
13. Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension 2006; November 20 (Epub ahead of print).
14. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17:1125-1133.
15. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538-542.
16. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98:772-776.
17. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362.
18. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
19. Dancey DR, Hanly PJ, Soong C, Lee B, Shepard J Jr, Hoffstein V. Gender differences in sleep apnea: the role of neck circumference. Chest 2003; 123:1544-1550.
20. Mortimore IL, Marshall I, Wraith PK, Sellar RJ, Douglas NJ. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med 1998; 157:280-283.
21. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC, et al. Left ventricular hypertrophy in severe obesity. Interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 2006; November 27 (Epub ahead of print).
22. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
23. Reid CM, Dart AM, Dewar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994; 12:291-301.
24. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992; 20:533-541.
25. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons - a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279:839-846.
26. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683- 2693.
27. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45:1035-1041.
28. Chaput JP, Tremblay A. Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol 2006; 62:793-803.
29. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005; 29:509-516.
30. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20:1873-1878.
31. Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 2005; 7:330-336.
32. Schmieder RE, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment. Br Med J 1993; 307:537-540.
33. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.
34. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37:250-254.
35. Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, Kreuzberg U. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005; 23:2313-2318.
36. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais, et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551-1562.